Biotech Damian Garde STAT Plus: For Eli Lilly’s head scientist, Alzheimer’s results cap a 25-year scientific quest
Health Isabella Cueto Moving xenotransplantation research into human trials will require adjusting our expectations, researchers say
Pharma Rachel Cohrs Zhang STAT Plus: Mark Cuban’s company is building a ‘parallel supply chain’ for prescription drugs
STAT Madness Isabella Cueto ‘Skinny, greasy mice,’ artificial cells, and tumor mapping: Researchers vie for STAT Madness championship
Politics Nicholas Florko STAT Plus: Califf admits controversy over FDA’s Alzheimer’s drug decision impacted experts’ trust in the agency
Biotech Megan Molteni STAT Plus: In the wake of big patent decision, it’s business as usual for CRISPR therapy developers
Biotech Claudia López Lloreda Messenger RNA vaccine pioneer Katalin Karikó shares her long journey to Covid-19 vaccines
Politics Lev Facher NIH’s Francis Collins: For Biden’s new research agency to succeed, it should prepare for some projects to fail
Health Eric Boodman STAT Plus: With fewer than 400 progeria patients worldwide, testing a CRISPR cure will be challenging
Politics Rachel Cohrs Zhang STAT Plus: FDA chief Janet Woodcock acknowledges agency may have misstepped in process leading up to Alzheimer’s drug approval
Health Helen Branswell The world will not exit Covid-19 pandemic without booster shots, vaccine developer says
